The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer
Deniz Tataroglu Ozyukseler1, Seval Ay2, Merve Turan1, Gulin Alkan3, Murat Ayhan1, Heves Surmeli1, Nedim Turan1, Hatice Odabas1, Mahmut Emre Yildirim11Department of Medical Oncology, Istanbul Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Türkiye, 2Department of Medical Oncology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Türkiye, 3Department of Medical Oncology, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Türkiye
Objectives: Although pancreatic cancer is comparatively rare, it's the seventh cause of cancer-related mortality in the world. Surgery is the sole curative treatment option but approximately 85% of patients are diagnosed at inoperable stages. The standard treatment options for the advanced staged disease are 5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy. In spite of those treatments, the 5-year survival rate is less than 5%. In this study, we aimed to evaluate the prognostic value of the systemic inflammation response index (SIRI). Methods: A retrospective, single-center study consisting of 103 patients from December 2015 to December 2019, was performed. The cut-off SIRI values were determined as 1.8×109. We determine whether the SIRI was an independent prognostic parameter. Results: We observed that the median OS for metastatic pancreatic cancer patients with SIRI values <1.8×109 was better than the patients with SIRI values?1.8×109 independent of the treatment choices (17.3 months vs 11.9 months). Conclusion: SIRI seems to be an accessible, and cost-effective parameter as a strong prognostic determiner for advanced pancreatic cancer. Its value is independent of the treatment choice. Keywords: Pancreatic adenocarcinoma, systemic inflammation response index, prognostic factor
Cite This Article
Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, Turan N, Odabas H, Yildirim M. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI. 2022; 6(3): 367-373
Corresponding Author: Deniz Tataroglu Ozyukseler